Han X, Xu Y, Ricciardi A, Xu J, Palanki R, Chowdhary V
bioRxiv. 2025; .
PMID: 40060499
PMC: 11888472.
DOI: 10.1101/2025.02.25.640222.
Bolideei M, Barzigar R, Gahrouei R, Mohebbi E, Haider K, Paul S
Stem Cell Rev Rep. 2025; .
PMID: 40014250
DOI: 10.1007/s12015-025-10857-0.
Perez A, Mavrothalassitis O, Chen J, Hellman J, Gropper M
Br J Anaesth. 2025; 134(3):839-852.
PMID: 39855935
PMC: 11867086.
DOI: 10.1016/j.bja.2024.11.040.
Fatima H, Singh D, Muhammad H, Acharya S, Aziz M
3 Biotech. 2024; 15(1):17.
PMID: 39711922
PMC: 11656010.
DOI: 10.1007/s13205-024-04186-1.
Yang J, Toughiri R, Gounder A, Scheibe D, Petrus M, Fink S
PLoS One. 2024; 19(11):e0307049.
PMID: 39504332
PMC: 11540224.
DOI: 10.1371/journal.pone.0307049.
Harnessing the evolving CRISPR/Cas9 for precision oncology.
Li T, Li S, Kang Y, Zhou J, Yi M
J Transl Med. 2024; 22(1):749.
PMID: 39118151
PMC: 11312220.
DOI: 10.1186/s12967-024-05570-4.
Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy.
Jin S, Sung J
Int J Mol Sci. 2024; 25(14).
PMID: 39062852
PMC: 11277092.
DOI: 10.3390/ijms25147612.
Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies.
Huang X, Ma Y, Ma G, Xia Y
Research (Wash D C). 2024; 7:0370.
PMID: 38894715
PMC: 11185168.
DOI: 10.34133/research.0370.
A mechanistic study on the tolerance of PAM distal end mismatch by SpCas9.
Dey D, Chakravarti R, Bhattacharjee O, Majumder S, Chaudhuri D, Ahmed K
J Biol Chem. 2024; 300(7):107439.
PMID: 38838774
PMC: 11267045.
DOI: 10.1016/j.jbc.2024.107439.
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.
Kayki-Mutlu G, Aksoyalp Z, Wojnowski L, Michel M
Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(5):2949-2970.
PMID: 38530400
PMC: 11074039.
DOI: 10.1007/s00210-024-03063-1.
Targeted nonviral delivery of genome editors in vivo.
Tsuchida C, Wasko K, Hamilton J, Doudna J
Proc Natl Acad Sci U S A. 2024; 121(11):e2307796121.
PMID: 38437567
PMC: 10945750.
DOI: 10.1073/pnas.2307796121.
Engineering approaches for RNA-based and cell-based osteoarthritis therapies.
DeJulius C, Walton B, Colazo J, dArcy R, Francini N, Brunger J
Nat Rev Rheumatol. 2024; 20(2):81-100.
PMID: 38253889
PMC: 11129836.
DOI: 10.1038/s41584-023-01067-4.
Exagamglogene Autotemcel: First Approval.
Hoy S
Mol Diagn Ther. 2024; 28(2):133-139.
PMID: 38228954
DOI: 10.1007/s40291-024-00696-z.
Gene therapy for sickle cell disease.
Leonard A, Tisdale J
Hematology Am Soc Hematol Educ Program. 2023; 2023(1):542-547.
PMID: 38066927
PMC: 10727030.
DOI: 10.1182/hematology.2023000487.
CRISPR-Cas9 Direct Fusions for Improved Genome Editing via Enhanced Homologous Recombination.
Tabassum T, Pietrogrande G, Healy M, Wolvetang E
Int J Mol Sci. 2023; 24(19).
PMID: 37834150
PMC: 10572186.
DOI: 10.3390/ijms241914701.
We need a genomics-savvy healthcare workforce.
Nat Med. 2023; 29(8):1877-1878.
PMID: 37587213
DOI: 10.1038/s41591-023-02522-1.
